HK1199023A1 - Substituted benzothienylpyrrolotriazines and uses thereof - Google Patents

Substituted benzothienylpyrrolotriazines and uses thereof

Info

Publication number
HK1199023A1
HK1199023A1 HK14112456.6A HK14112456A HK1199023A1 HK 1199023 A1 HK1199023 A1 HK 1199023A1 HK 14112456 A HK14112456 A HK 14112456A HK 1199023 A1 HK1199023 A1 HK 1199023A1
Authority
HK
Hong Kong
Prior art keywords
benzothienylpyrrolotriazines
substituted
substituted benzothienylpyrrolotriazines
Prior art date
Application number
HK14112456.6A
Other languages
English (en)
Chinese (zh)
Inventor
Mario Lobell
Walter Hbsch
Hartmut Schirok
Mlanie Hroult
Dirk Brohm
Marie-Pierre Collin
Sylvia Grnewald
Klemens Lustig
Ulf Bmer
Verena Voehringer
Niels Lindner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1199023A1 publication Critical patent/HK1199023A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14112456.6A 2012-02-23 2014-12-11 Substituted benzothienylpyrrolotriazines and uses thereof HK1199023A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12156759 2012-02-23
PCT/EP2013/053378 WO2013124316A1 (en) 2012-02-23 2013-02-20 Substituted benzothienyl-pyrrolotriazines and uses thereof

Publications (1)

Publication Number Publication Date
HK1199023A1 true HK1199023A1 (en) 2015-06-19

Family

ID=47749817

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112456.6A HK1199023A1 (en) 2012-02-23 2014-12-11 Substituted benzothienylpyrrolotriazines and uses thereof

Country Status (8)

Country Link
US (1) US9475815B2 (xx)
EP (1) EP2817311B1 (xx)
JP (1) JP6082033B2 (xx)
CN (1) CN104136439B (xx)
CA (1) CA2865021C (xx)
ES (1) ES2581065T3 (xx)
HK (1) HK1199023A1 (xx)
WO (1) WO2013124316A1 (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9557119B2 (en) * 2009-05-08 2017-01-31 Arvos Inc. Heat transfer sheet for rotary regenerative heat exchanger
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP3822273B1 (en) 2012-06-13 2024-04-10 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2015008844A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Fgfr阻害剤耐性癌の治療薬
AU2014291161B2 (en) 2013-07-18 2018-04-26 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of FGFR inhibitor
CN103757026B (zh) 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
MA39481A (fr) * 2014-03-03 2015-09-11 Synta Pharmaceuticals Corp Thérapies ciblées
US10918698B2 (en) 2014-03-29 2021-02-16 Intas Pharmaceuticals Ltd. Lyophilized pharmaceutical composition of Fc-peptide fusion protein
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
ES2807785T3 (es) 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
JP6860585B2 (ja) 2016-03-09 2021-04-14 ヤンセン バイオファーマ インク. 非環状抗ウイルス 優先出願の参照による組み込み
WO2017153789A1 (en) * 2016-03-11 2017-09-14 Vichem Chemie Kutató Kft. Benzo[b]thiophene derivatives and their use for the inhibition of fibroblast growth factor receptor kinases (fgfrs) for the use of neo- and hyperplasia therapies
SG11201808582RA (en) 2016-03-28 2018-10-30 Incyte Corp Pyrrolotriazine compounds as tam inhibitors
CN107417687A (zh) * 2016-05-24 2017-12-01 中国科学院上海药物研究所 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7341122B2 (ja) * 2017-08-15 2023-09-08 石薬集団中奇制薬技術(石家庄)有限公司 Fgfr阻害剤及びその医薬品の用途
WO2019034075A1 (zh) * 2017-08-15 2019-02-21 南京明德新药研发股份有限公司 Fgfr和egfr抑制剂
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
EP3813800A1 (en) 2018-06-29 2021-05-05 Incyte Corporation Formulations of an axl/mer inhibitor
US20220177475A1 (en) 2019-02-15 2022-06-09 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Fgfr inhibitor compound in solid form and preparation method therefor
WO2020170355A1 (ja) * 2019-02-20 2020-08-27 大鵬薬品工業株式会社 Fgfr1変異腫瘍の治療方法
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114667282A (zh) * 2019-10-22 2022-06-24 昊运股份有限公司 嘧啶酰胺化合物及治疗癌症的方法
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634045T2 (de) 1995-10-31 2005-05-19 Eli Lilly And Co., Indianapolis Antithrombotische diamine
BR0010482A (pt) * 1999-05-21 2002-04-23 Bristol Myers Squibb Co Inibidores pirrolotriazìnicos de cinases
TR200201506T2 (tr) 1999-09-17 2002-10-21 Abbott Gmbh & Co. Kg Terapötik maddeler olarak kinaz inhibitörleri
SG132683A1 (en) 2003-10-15 2007-06-28 Osi Pharm Inc Imidazopyrazine tyrosine kinase inhibitors
DK1740591T3 (da) 2004-04-02 2009-10-26 Osi Pharm Inc Heterobicykliske proteinkinaseinhibitorer substitueret med en 6,6-biocyclisk ring
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
ES2401099T3 (es) 2005-11-02 2013-04-16 Bayer Intellectual Property Gmbh Pirrolo[2,1-F] [1,2,4]-triazin-4-ilaminas como inhibidores de la quinasa IGF-1R para el tratamiento del cáncer y de otras enfermedades hiperproliferativas
PT1951724E (pt) * 2005-11-17 2011-08-02 Osi Pharm Inc Inibidores mtor fundidos bicíclicos
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5193876B2 (ja) 2005-12-02 2013-05-08 バイエル・ヘルスケア・エルエルシー オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
JP5512975B2 (ja) 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
AU2008304620A1 (en) * 2007-09-25 2009-04-02 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010126960A1 (en) 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds

Also Published As

Publication number Publication date
ES2581065T3 (es) 2016-08-31
US9475815B2 (en) 2016-10-25
CN104136439B (zh) 2017-01-18
JP2015508087A (ja) 2015-03-16
EP2817311A1 (en) 2014-12-31
EP2817311B1 (en) 2016-04-06
WO2013124316A1 (en) 2013-08-29
US20150031676A1 (en) 2015-01-29
CA2865021C (en) 2020-06-30
JP6082033B2 (ja) 2017-02-15
CA2865021A1 (en) 2013-08-29
CN104136439A (zh) 2014-11-05

Similar Documents

Publication Publication Date Title
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HK1203493A1 (en) Substituted azabicycles and use thereof
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
HK1210949A1 (en) Combinations and uses thereof
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
HK1198833A1 (en) N-acylpeptide derivatives and their uses n-
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
PL2882708T3 (pl) Nowe związki i ich zastosowania
IL237400A0 (en) Rhizobacteria and its uses
HK1207154A1 (en) C1q-adiponectin complex and use thereof c1q-
PL2830587T3 (pl) Kompozycja o balansującym i ochronnym wpływie na skórę
GB201222541D0 (en) Kiddibidet and pottibidet
GB201222342D0 (en) Compounds and uses thereof
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201214749D0 (en) Compounds and their uses
GB201207075D0 (en) New compounds and uses
GB201206973D0 (en) New compounds and uses
GB201206055D0 (en) New compounds and uses
GB201206998D0 (en) New compound and uses
GB201213726D0 (en) Novel compounds and their use
GB201220595D0 (en) Keysafe application